drugset / Trial / NCT02791035
Correlation Between Change of HbA1c, Urinary Glucose Excretion and Other Factors in Patients Treated With Ipragliflozin
Phase 4
Completed
100 enrolled
Asan Medical Center
Astellas Pharma Korea, Inc. · collabKyung Hee University Hospital at Gangdong · collabSamsung Medical Center · collabSeverance Hospital · collab
NaSingle-groupOpen-labelOther
Summary
The purpose of this study is to examine the correlation between change of HbA1c, urinary glucose excretion and other factors when ipragliflozin is added to preexisting therapy in subjects with type 2 diabetes.
Timeline
- Start
- 2016-06
- Primary completion
- 2017-03
- Completion
- 2017-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ipragliflozin | Small molecule | 50 mg | Oral |